Tualang honey promotes apoptotic cell death induced by tamoxifen in breast cancer cell lines

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Yaacob, Nik Soriani ^a   Nengsih, Agustine ^a   Norazmi, Mohd Nor ^b  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; ESTROGEN RECEPTOR; TAMOXIFEN; TUALANG HONEY EXTRACT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HONEY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; TUALANG HONEY;

EID: 84874866273     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/989841     Document Type: Article

References (44)

1. Gottesman M. M., Mechanisms of cancer drug resistance. Annual Review of Medicine 2002 53 615 627 2-s2.0-0036176510 10.1146/annurev.med.53.082901.103929 (Pubitemid 34177898)
2. Li C. I., Daling J. R., Malone K. E., Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. Journal of Clinical Oncology 2003 21 1 28 34 2-s2.0-0037208632
3. Ravdin P. M., Cronin K. A., Howlader N., Berg C. D., Chlebowski R. T., Feuer E. J., Edwards B. K., Berry D. A., The decrease in breast-cancer incidence in 2003 in the United States. The New England Journal of Medicine 2007 356 16 1670 1674 2-s2.0-34247241630 10.1056/NEJMsr070105 (Pubitemid 46631679)
4. Osborne C. K., Tamoxifen in the treatment of breast cancer. The New English Journal of Medicine 1998 339 1609 1617
5. Cersosimo R. J., Tamoxifen for prevention of breast cancer. The Annals of Pharmacotherapy 2003 37 2 268 273 (Pubitemid 36172870)
6. Fisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N., Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 1998 90 18 1371 1388 2-s2.0-0032537990 (Pubitemid 28439961)
7. Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L., Cronin W. M., Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Journal of the National Cancer Institute 1994 86 7 527 537 2-s2.0-0028208456 (Pubitemid 24111008)
8. Kim S. Y., Suzuki N., Laxmi Y. R. S., Shibutani S., Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metabolism Reviews 2004 36 2 199 218 2-s2.0-3042653655 10.1081/DMR-120033997 (Pubitemid 38802486)
9. Hemminki K., Rajaniemi H., Koskinen M., Hansson J., Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients. Carcinogenesis 1997 18 1 9 13 2-s2.0-0031409631 10.1093/carcin/18.1.9 (Pubitemid 28134610)
10. Hemminki K., Rajaniemi H., Lindahl B., Moberger B., Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Research 1996 56 19 4374 4377 2-s2.0-0029745072 (Pubitemid 26330442)
11. Shibutani S., Ravindernath A., Suzuki N., Terashima I., Sugarman S. M., Grollman A. P., Pearl M. L., Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000 21 8 1461 1467 2-s2.0-0033859582 (Pubitemid 30601641)
12. Clemons M., Danson S., Howell A., Tamoxifen ("Nolvadex"): a review. Cancer Treatment Review 2002 28 165 180
13. Early Breast Cancer Triallists' Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 2005 365 9472 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
14. Fabricant D. S., Farnsworth N. R., The value of plants used in traditional medicine for drug discovery. Environmental Health Perspectives 2001 109 1 69 75 2-s2.0-0035044430 (Pubitemid 32303231)
15. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 2004 56 2 185 229 2-s2.0-2642566088 10.1124/pr.56.2.6 (Pubitemid 38720829)
16. Ring A. E., Ellis P. A., Taxanes in the treatment of early breast cancer. Cancer Treatment Reviews 2005 31 8 618 627 2-s2.0-27944508718 10.1016/j.ctrv.2005.09.005 (Pubitemid 41662888)
17. Jordan M. A., Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Current Medicinal Chemistry 2002 2 1 1 17 2-s2.0-0036083301 (Pubitemid 34649866)
18. Galletti E., Magnani M., Renzulli M. L., Botta M., Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007 2 7 920 942 2-s2.0-41949119102 10.1002/cmdc.200600308
19. Fauzi A. N., Norazmi M. N., Yaacob N. S., Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines. Food and Chemical Toxicology 2011 49 4 871 878 2-s2.0-79952451695 10.1016/j.fct.2010.12.010
20. Nurul Syazana M. S., Halim A. S., Gan S. H., Shamsuddin S., Antiproliferative effect of methanolic extraction of tualang honey on human keloid fibroblasts. BMC Complementary and Alternative Medicine 2011 11, article 82 10.1186/1472-6882-11-82
21. Mohamed M., Sirajudeen K. N. S., Swamy M., Yaacob N. S., Sulaiman S. A., Studies on the antioxidant properties of tualang honey of Malaysia. African Journal of Traditional, Complementary and Alternative Medicines 2010 7 1 59 63 2-s2.0-77956225665
22. Khalil M. I., Alam N., Moniruzzaman M., Sulaiman S. A., Gan S. H., Phenolic acid composition and antioxidant properties of Malaysian honeys. Journal of Food Science 2011 76 6 C921 C928 2-s2.0-79961117194 10.1111/j.1750-3841.2011.02282.x
23. Kishore R. K., Halim A. S., Syazana M. S. N., Sirajudeen K. N. S., Tualang honey has higher phenolic content and greater radical scavenging activity compared with other honey sources. Nutrition Research 2011 31 4 322 325 2-s2.0-79955470092 10.1016/j.nutres.2011.03.001
24. Ellis P. A., Saccani-Jotti G., Clarke R., Johnston S. R. D., Anderson E., Howell A., A'Hern R., Salter J., Detre S., Nicholson R., Robertson J., Smith I. E., Dowsett M., Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. International Journal of Cancer 1997 72 4 608 613 (Pubitemid 27356161)
25. Petinari L., Kohn L. K., De Carvalho J. E., Genari S. C., Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation in vitro. Cell Biology International 2004 28 7 531 539 2-s2.0-3142523443 10.1016/j.cellbi.2004.04.008 (Pubitemid 38903204)
26. Mandlekar S., Kong A. N. T., Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001 6 6 469 477 2-s2.0-0035181465 10.1023/A:1012437607881 (Pubitemid 33078758)
27. Waterhouse D. N., Gelmon K. A., Klasa R., Chi K., Wasan E., Edwards L., Tucker C., Zastre J., Zhang Y. Z., Yapp D., Dragowska W., Dunn S., Dedhar S., Bally M. B., Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Current Cancer Drug Targets 2006 6 6 455 489 10.2174/156800906778194586 (Pubitemid 44371970)
28. von Minckwitz G., Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opinion on Pharmacotherapy 2007 8 4 485 495 2-s2.0-33947285105 10.1517/14656566.8.4.485 (Pubitemid 46416417)
29. Oostendorp L. J. M., Stalmeier P. F. M., Donders A. R. T., Ottevanger P. B., Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. The Lancet Oncology 2011 12 11 1053 1061 10.1016/S1470-2045(11)70045-6
30. Argiris A., Wang C. X., Whalen S. G., DiGiovanna M. P., Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clinical Cancer Research 2004 10 4 1409 1420 2-s2.0-1642406972 10.1158/1078-0432.CCR-1060-02 (Pubitemid 38365236)
31. Treeck O., Wackwitz B., Haus U., Ortmann O., Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecologic Oncology 2006 102 2 292 299 2-s2.0-33745903146 10.1016/j.ygyno.2005.12.019 (Pubitemid 44041641)
32. Yu H. N., Noh E. M., Lee Y. R., Roh S. G., Song E. K., Han M. K., Lee Y. C., Shim I. K., Lee S. J., Jung S. H., Kim J. S., Youn H. J., Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. Biochemical and Biophysical Research Communications 2008 377 1 242 247 2-s2.0-54449088704 10.1016/j.bbrc.2008.09.111
33. Brüning A., Friese K., Burges A., Mylonas I., Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. Breast Cancer Research 2010 12 4, article R45 2-s2.0-78650873029 10.1186/bcr2602
34. Chakraborty A. K., Welsh A., Digiovanna M. P., Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Research and Treatment 2010 120 2 327 335 2-s2.0-77950691907 10.1007/s10549-009-0382-5
35. Wang J., Liu W., Zhao Q., Qi Q., Lu N., Yang Y., Nei F. F., Rong J. J., You Q. D., Guo Q. L., Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 2009 256 1-2 135 140 2-s2.0-58149218002 10.1016/j.tox.2008.11.014
36. Raja S. M., Clubb R. J., Ortega-Cava C., Williams S. H., Bailey T. A., Duan L., Zhao X., Reddi A. L., Nyong A. M., Natarajan A., Band V., Band H., Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biology and Therapy 2011 11 2 263 276 2-s2.0-78751506175 10.4161/cbt.11.2.13959
37. Sartippour M. R., Pietras R., Marquez-Garban D. C., Chen H. W., Heber D., Henning S. M., Sartippour G., Zhang L., Lu M., Weinberg O., Rao J. Y., Brooks M. N., The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis 2006 27 12 2424 2433 2-s2.0-33845363659 10.1093/carcin/bgl066 (Pubitemid 44884099)
38. Petit P. X., Lecoeur H., Zorn E., Dauguet C., Mignotte B., Gougeon M. L., Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. Journal of Cell Biology 1995 130 1 157 167 2-s2.0-0029036412 10.1083/jcb.130.1.157
39. Green D. R., Kroemer G., The pathophysiology of mitochondrial cell death. Science 2004 305 5684 626 629 2-s2.0-3442886811 10.1126/science.1099320 (Pubitemid 39006738)
40. 2+ uptake by estrogen receptor agonists and antagonists. British Journal of Pharmacology 2005 145 7 862 871 2-s2.0-23744443498 10.1038/sj.bjp.0706265 (Pubitemid 41129007)
41. Jaganathan S. K., Mandal M., Involvement of non-protein thiols, mitochondrial dysfunction, reactive oxygen species and p53 in honey-induced apoptosis. Investigational New Drugs 2010 28 5 624 633 2-s2.0-77956058693 10.1007/s10637-009-9302-0
42. Kim R., Emi M., Tanabe K., Role of mitochondria as the gardens of cell death. Cancer Chemotherapy and Pharmacology 2006 57 5 545 553 2-s2.0-32544448056 10.1007/s00280-005-0111-7 (Pubitemid 43237837)
43. Belizário J. E., Alves I., Occhiucci J. M., Garay-Malpartida M., Sesso A., A mechanistic view of mitochondrial death decision pores. Brazilian Journal of Medical and Biological Research 2007 40 8 1011 1024 2-s2.0-34547748907 (Pubitemid 47232855)
44. Gakhar G., Hua D. H., Nguyen T. A., Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells. Anti-Cancer Drugs 2010 21 1 77 88 2-s2.0-74349092183 10.1097/CAD.0b013e328333d557